Genmab — Maj 2019

[E_L]

JNJ putting the JNJ-61186372 in the list of 10 top candidates for $1 billion-​plus in revenue

[E_L]

that is the EGFR + cMet

[Sukkeralf]

Nice - link?

[Sukkeralf]

Data at ASCO could be very good

[E_L]

got it from this, but i'll see if
it is on the JNJ website also later https://endpts.com/jj-polishes-up-some-new-blockbuster-candidates-as-it-spotlights-a-new-lineup-in-late-stage-development/

[E_L]

and 'nice' i think is a bit understated

[E_L]

actually JNJ-957 is also in the list!!

[E_L]

=BCMA/CD3

[Solsen]

Sounds
very nice. EGFR + cMet are double digit.

[Sukkeralf]

I have a feeling that Janssen keeps BCMA/CD3 under the radar - and suddenly pops up with the best data and a faster way to market. Just repeating the CD38 race

[Sukkeralf]

And in the future maybe in combination with dara

[Helge_LarsenPI-redaktør]

Welcome to Genmab

(www.genmab.com)

[Sukkeralf]

We are getting so close to good clinical vallidation of DuoBody and one could wish for good data on DR5/DR5 also - then both platforms are vallidated which make Genmabs money drain more accep
table

[gentogen]

https://johnsonandjohnson.gcs-web.com/static-files/7b8bef74-237e-4a05-82c3-79a8f8789f89

[gentogen]

slide 21

[E_L]

yes, very true Sukkeralf. (thanks @gentogen , i couldnt find it)

[Solsen]

Jnj 7564 er vel også Genmabs

[Sukkeralf]

Ja faktisk 3 stk - fantastisk

[Solsen]

JNJ-7564 GPRC5D/CD3, JNJ-7957 BCMA/CD3, JNJ-6372 EGFR/c-Met ...

[Solsen]

Ketchubeffekten